Member-only story
Society
Cell and Gene Therapies: An Opportunity for Catalyzing Public-Private Partnerships
Highlights from the American Society of Gene & Cell Therapy’s 2022 Policy Summit
Cell and gene therapies have the potential to treat and cure some of the most debilitating diseases that humanity faces
These therapies could potentially treat and cure diseases like cancer, diabetes, and cystic fibrosis. The FDA has already approved several cellular and gene therapy products including some that focus on the treatment of ß-thalassemia, Spinal Muscular Atrophy (Type I), biallelic RPE65 mutation-associated retinal dystrophy, relapsed or refractory multiple myeloma, and single or multiple symptomatic, full-thickness cartilage defects of the knee.
The fifth annual ASGCT Policy Summit brought together stakeholders from a variety of interest groups to discuss some of the most pressing pain points facing the cell and gene therapy field. Over the course of the two-day Summit, these stakeholders evaluated the pain points and how they inform the policies that shape the field.